Microbiome Modulator

Lactobacillus rhamnosus GG

Lacticaseibacillus rhamnosus GG (ATCC 53103)

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

10-20 billion CFU daily for AAD prevention and acute diarrhea support, taken with or without food

watchEffect Window

LGG begins colonizing the intestinal mucosa within hours of ingestion. For AAD prevention, the protective effect is present throughout the supplementation period. Benefit is tied to active use rather than to a delayed cumulative effect.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Lactobacillus rhamnosus GG is one of the most studied probiotic strains in the world, with the strongest evidence for preventing antibiotic-associated diarrhea and reducing hospital-acquired diarrhea risk in children.

LGG has strain-specific meta-analytic support for roughly halving antibiotic-associated diarrhea risk, and it is the only probiotic strain formally recommended by ESPGHAN for prevention of nosocomial diarrhea in hospitalized children. Evidence for treating acute gastroenteritis in children is more mixed, with earlier positive results tempered by large recent trials showing modest or absent benefit in well-resourced settings. Perinatal use for atopic dermatitis prevention is suggestive but inconsistent. Safety is excellent in immunocompetent individuals, but LGG should not be used in critically ill or severely immunocompromised patients due to rare but documented bacteremia risk.

LGG temporarily colonizes the intestinal mucosa through SpaCBA pili-mediated adhesion, competes with pathogens for binding sites, strengthens the epithelial barrier by upregulating tight junction proteins, produces antimicrobial substances, and modulates innate and adaptive immune responses including increased secretory IgA production. These mechanisms converge to reinforce gut defenses during periods of disruption from antibiotics, acute infection, or hospitalization.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Reduced antibiotic-associated diarrhea risk during and after antibiotic courses
  • Reduced nosocomial diarrhea risk in hospitalized children

Secondary Outcomes

  • Modestly reduced diarrhea duration in children with acute gastroenteritis
  • Possible reduction in atopic eczema incidence with perinatal use in high-risk infants (inconsistent evidence)

Safety

Contraindications and Interactions

Contraindications

  • Severe immunocompromise (active chemotherapy, organ transplant on immunosuppressants, advanced HIV with low CD4 count)
  • Critical illness or ICU admission
  • Short bowel syndrome or severely disrupted intestinal barrier
  • Neonates in intensive care
  • Known allergy to LGG or product excipients

Side effects

  • Gas or bloating
  • Mild abdominal discomfort
  • Transient increase in stool frequency

Interactions

  • Antibiotics
  • Immunosuppressive medications

Avoid if

  • Severely immunocompromised or critically ill
  • Admitted to an ICU or neonatal intensive care unit
  • Living with short bowel syndrome or severely disrupted intestinal barrier
  • Unexplained fever develops while taking LGG in a vulnerable population

Evidence

Study-level References

lgg-SRC-001Systematic review and meta-analysis of randomized controlled trials
Sourceopen_in_new

Szajewska H, Kołodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015;42(10):1149-1157.

Population: Children and adults receiving antibiotics from 12 RCTs (n=1,499)

Dose protocol: LGG at various doses across 12 RCTs, most commonly 10-20 billion CFU daily during antibiotic courses.

Key findings: LGG reduced AAD incidence from 22.4% to 12.3% (RR 0.49, 95% CI 0.29-0.83). Significant in children, non-significant in adults overall, strongly significant in H. pylori eradication subgroup.

Notes: The definitive strain-specific meta-analysis for LGG and AAD. Distinguishes LGG from the broader multi-strain probiotic literature.

Paper content

Landmark strain-specific meta-analysis confirming that Lactobacillus rhamnosus GG reduces antibiotic-associated diarrhea risk by approximately half compared with placebo or no treatment (RR 0.49, 95% CI 0.29-0.83). The effect was significant in children (RR 0.48, moderate quality evidence) but did not reach significance in adults overall (RR 0.48, low quality evidence), except in the subgroup receiving antibiotics for H. pylori eradication (RR 0.26). This is the most important strain-specific pooled analysis for LGG and AAD prevention, distinguishing LGG from the broader probiotic literature by analyzing only trials using this specific strain.

lgg-SRC-002Systematic review and meta-analysis of randomized controlled trials
Sourceopen_in_new

Szajewska H, Kołodziej M, Gieruszczak-Białek D, Skórka A, Ruszczyński M, Shamir R. Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children - a 2019 update. Aliment Pharmacol Ther. 2019;49(11):1376-1384.

Population: Children with acute gastroenteritis from 18 RCTs (n=4,208)

Dose protocol: LGG at various doses across 18 RCTs in children with acute gastroenteritis.

Key findings: LGG reduced diarrhea duration by approximately one day and shortened hospitalization. Effect was more pronounced in European studies. Two large 2018 North American RCTs found no benefit.

Notes: Important because it honestly acknowledges the tension between earlier positive pooled results and recent large negative trials. Sets realistic expectations for this indication.

Paper content

Updated 2019 meta-analysis of 18 RCTs (n=4,208 children) assessing LGG for treatment of acute gastroenteritis. LGG reduced diarrhea duration by about one day overall and shortened hospitalization in inpatient settings. The effect was more pronounced in European populations. However, the authors noted high heterogeneity across trials and acknowledged that two large North American RCTs (the 2018 NEJM Schnadower trial and the Freedman trial) found no significant benefit of LGG over placebo for acute gastroenteritis in children treated in emergency departments. The authors concluded that LGG has some evidence of benefit but the clinical relevance is modest, particularly in well-resourced settings with access to oral rehydration therapy.

lgg-SRC-003Systematic review and ESPGHAN guideline based on meta-analysis of randomized controlled trials
Sourceopen_in_new

Hojsak I, Szajewska H, Canani RB, et al. Probiotics for the Prevention of Nosocomial Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2018;66(1):3-9.

Population: Hospitalized children at risk of nosocomial diarrhea from 8 RCTs, with 3 RCTs specifically evaluating LGG (n=1,823 for LGG)

Dose protocol: LGG at least 1 billion CFU daily for duration of hospital stay in 2 RCTs (n=1,823).

Key findings: LGG reduced nosocomial diarrhea from 13.9% to 5.2% (RR 0.35, 95% CI 0.19-0.65). ESPGHAN formally recommends LGG as the probiotic of choice for this indication.

Notes: The strongest guideline-level endorsement for any single probiotic strain in nosocomial diarrhea prevention. LGG is the only strain that met the threshold for a formal recommendation.

Paper content

ESPGHAN guideline and systematic review evaluating probiotics for nosocomial diarrhea prevention in hospitalized children. LGG was the only probiotic strain that met the threshold for a formal recommendation. Based on 2 RCTs with 1,823 children, LGG reduced nosocomial diarrhea risk from 13.9% to 5.2% (RR 0.35, 95% CI 0.19-0.65). The Working Group recommended LGG at a minimum dose of 1 billion CFU daily for the duration of hospital stay if probiotics for nosocomial diarrhea prevention are considered. This is the strongest guideline-level endorsement for any single probiotic strain in this specific indication.

lgg-SRC-004Clinical practice guideline based on systematic reviews and meta-analyses
Sourceopen_in_new

Szajewska H, Berni Canani R, Domellöf M, et al. Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr. 2023;76(2):232-247.

Population: Children with gastrointestinal disorders. Recommendations cover acute gastroenteritis treatment, antibiotic-associated diarrhea prevention, nosocomial diarrhea prevention, and other pediatric GI conditions.

Dose protocol: Comprehensive guideline covering multiple pediatric GI indications with strain-specific dosing recommendations.

Key findings: 2023 ESPGHAN position paper confirming LGG as one of only two recommended strains for AAD prevention and the sole recommended strain for nosocomial diarrhea prevention. Conditional recommendation maintained for acute gastroenteritis with reduced certainty.

Notes: The most authoritative current clinical guideline for strain-specific probiotic use in pediatric gastroenterology.

Paper content

Comprehensive 2023 ESPGHAN position paper updating clinical recommendations for probiotics in pediatric GI disorders. LGG is one of only two probiotic strains (alongside S. boulardii) recommended for antibiotic-associated diarrhea prevention. LGG also received a conditional recommendation for treatment of acute gastroenteritis (with the caveat that certainty of evidence is low and recent large RCTs have questioned the magnitude of benefit). LGG remains the only strain recommended for nosocomial diarrhea prevention. This guideline represents the current clinical consensus for strain-specific probiotic use in pediatric gastroenterology and provides the most authoritative framing for which indications have enough evidence to support real-world use.

lgg-SRC-005Systematic review and meta-analysis of randomized trials
Sourceopen_in_new

Voigt J, Lele M. Lactobacillus rhamnosus Used in the Perinatal Period for the Prevention of Atopic Dermatitis in Infants: A Systematic Review and Meta-Analysis of Randomized Trials. Am J Clin Dermatol. 2022;23(6):801-811. doi:10.1007/s40257-022-00723-x. PMID:36161401.

Population: Mother-infant pairs in randomized perinatal L. rhamnosus trials, generally enriched for family history of atopy.

Dose protocol: Perinatal maternal and/or infant L. rhamnosus supplementation across 11 randomized trials with follow-up through childhood.

Key findings: Meta-analysis found lower atopic eczema incidence at up to 2 years and at 6 to 7 years, but findings were weaker or not significant at later follow-up windows.

Notes: Useful for supporting the exploratory eczema-prevention claim while preserving the low-confidence framing because attrition and mixed trial designs remain important limitations.

Paper content

Meta-analysis of 11 randomized trials found lower atopic eczema incidence with perinatal L. rhamnosus use at up to 2 years and at 6 to 7 years, but not clearly at 4 to 5 years or 10 to 11 years. High attrition and mixed strain protocols temper long-term confidence.

lgg-SRC-006Systematic review and meta-analysis of randomized controlled trials and observational studies.
Sourceopen_in_new

Ananthan A, Balasubramanian H, Rath C, Muthusamy S, Rao S, Patole S. Lactobacillus rhamnosus GG as a probiotic for preterm infants: a strain specific systematic review and meta-analysis. Eur J Clin Nutr. 2024;78(10):830-846. doi:10.1038/s41430-024-01474-0. PMID:39060543.

Population: Preterm infants in neonatal intensive care or hospital settings.

Dose protocol: Strain-specific SR and MA of LGG as sole probiotic in preterm infants. 5 RCTs (n=851) for NEC, 7 RCTs (n=1,037) for late-onset sepsis.

Key findings: LGG significantly reduced NEC stage II or greater risk (RR 0.50, P=0.03). No significant effect on late-onset sepsis, mortality, or hospital stay.

Notes: Adds a strain-specific NEC prevention signal for preterm infants, extending LGG evidence beyond the AAD and nosocomial diarrhea indications.

Paper content

This strain-specific systematic review and meta-analysis evaluated LGG (ATCC 53103) as the sole probiotic for preterm infants. Pooling 5 RCTs (n=851), LGG significantly reduced the risk of necrotizing enterocolitis (NEC) stage II or greater (RR 0.50, P=0.03). However, no significant benefits were found for late-onset sepsis, mortality, time to full enteral feeds, or hospital stay duration. Observational studies did not replicate the NEC benefit. This is an important strain-specific analysis because it separates LGG from the broader multi-strain probiotic NEC literature and provides a cleaner estimate of what LGG alone can achieve in this vulnerable population. The NEC benefit adds to the existing evidence for LGG in pediatric GI protection.

Guides

Setup

Help